Dermbits

Dermbits

Welcome to Dermbits! Watch short videos of KOLs answering your questions
What is the role of the IL-13 pathway in AD pathogenesis and treatment?
0:45
May 1, 2025Atopic Dermatitis

What is the role of the IL-13 pathway in AD pathogenesis and treatment?

-

What is the relationship between itch improvement and overall AD control?
0:49
May 1, 2025Atopic Dermatitis

What is the relationship between itch improvement and overall AD control?

-

What is the role of IL-13 in driving itch in AD?
0:50
May 1, 2025Atopic Dermatitis

What is the role of IL-13 in driving itch in AD?

-

How can dermatologists define a patient with moderate AD, and what clinical markers guide this classification?
1:13
May 1, 2025Atopic Dermatitis

How can dermatologists define a patient with moderate AD, and what clinical markers guide this classification?

-

Why aren’t more patients with moderate AD treated with advanced systemic therapies?
1:00
May 1, 2025Atopic Dermatitis

Why aren’t more patients with moderate AD treated with advanced systemic therapies?

-

How can dermatologists decide when to escalate to a systemic therapy for a patient with AD?
0:53
May 1, 2025Atopic Dermatitis

How can dermatologists decide when to escalate to a systemic therapy for a patient with AD?

-

What are the expected timelines for clinical improvement when initiating systemic therapies for AD?
1:06
May 1, 2025Atopic Dermatitis

What are the expected timelines for clinical improvement when initiating systemic therapies for AD?

-

How do you educate patients about the chronic nature of AD to improve adherence?
0:51
May 1, 2025Atopic Dermatitis

How do you educate patients about the chronic nature of AD to improve adherence?

-

How do you counsel patients on symptom fluctuation and reinforce the importance of treatment adherence?
1:07
May 1, 2025Atopic Dermatitis

How do you counsel patients on symptom fluctuation and reinforce the importance of treatment adherence?

-

How can dermatologists effectively recognize and manage mental health comorbidities in patients with AD?
1:10
May 1, 2025Atopic Dermatitis

How can dermatologists effectively recognize and manage mental health comorbidities in patients with AD?

-

What conditions should be considered in the clinical differential diagnosis of vitiligo?
1:19
May 1, 2025Vitiligo

What conditions should be considered in the clinical differential diagnosis of vitiligo?

-

What is the epidemiology of vitiligo?
0:58
May 1, 2025Vitiligo

What is the epidemiology of vitiligo?

-

What is the role of inflammation in the pathogenesis of vitiligo?
1:08
May 1, 2025Vitiligo

What is the role of inflammation in the pathogenesis of vitiligo?

-

How can patients with vitiligo get involved in support groups?
0:52
May 1, 2025Vitiligo

How can patients with vitiligo get involved in support groups?

-

What is the Koebner phenomenon in vitiligo?
1:04
May 1, 2025Vitiligo

What is the Koebner phenomenon in vitiligo?

-

What are some dermatologic syndromes that present with vitiligo?
0:59
May 1, 2025Vitiligo

What are some dermatologic syndromes that present with vitiligo?

-

What are some rare clinical subtypes of vitiligo?
1:08
May 1, 2025Vitiligo

What are some rare clinical subtypes of vitiligo?

-

How can vitiligo be distinguished from contact leukoderma?
0:58
May 1, 2025Vitiligo

How can vitiligo be distinguished from contact leukoderma?

-

Is it common for patients with vitiligo to have other autoimmune diseases?
1:06
May 1, 2025Vitiligo

Is it common for patients with vitiligo to have other autoimmune diseases?

-

Can vitiligo be treated with surgical intervention?
1:18
May 1, 2025Vitiligo

Can vitiligo be treated with surgical intervention?

-

Can ruxolitinib be used as a maintenance therapy in patients with vitiligo once repigmentation has been achieved?
0:51
Apr 2, 2025Vitiligo

Can ruxolitinib be used as a maintenance therapy in patients with vitiligo once repigmentation has been achieved?

-

Are there any recommendations for tapering ruxolitinib for vitiligo to minimize rebound depigmentation?
0:30
Apr 2, 2025Vitiligo

Are there any recommendations for tapering ruxolitinib for vitiligo to minimize rebound depigmentation?

-

Do topical calcineurin inhibitors and corticosteroids have a role as adjunctive therapy with ruxolitinib, or should they be replaced entirely?
0:41
Apr 2, 2025Vitiligo

Do topical calcineurin inhibitors and corticosteroids have a role as adjunctive therapy with ruxolitinib, or should they be replaced entirely?

-

Can ruxolitinib for vitiligo be used with therapeutic biologics?
0:36
Apr 2, 2025Vitiligo

Can ruxolitinib for vitiligo be used with therapeutic biologics?

-